Englumafusp alfa

Englumafusp alfa (RO7227166) is a fusion protein developed by Hoffmann-La Roche. Its target is CD19 (the sponsor names CD19 x 4-1BBL). The sponsor states: Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma. ClinicalTrials.gov describes the intervention as: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT04077723, plans to enrol 498 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.